HIV drug lenacapavir binds the immature Gag protein and forces the virus to build giant, non-infectious particles more than 200 nanometers wide.
Research published September 3 in Proceedings of the National Academy of Sciences shows that lenacapavir, a long-acting capsid inhibitor already used to prevent and treat HIV-1, disrupts late-stage viral assembly in a previously unknown way.
The study was led by Lecturer Kazuaki Monde of Kumamoto University and Professor Yasumasa Iwatani of Hamamatsu University School of Medicine, with collaborators from the University of Miyazaki, the National Hospital Organization Nagoya Medical Center, and Tokyo University of Technology.
The experimental effort involved researchers from the Department of Microbiology, Faculty of Life Sciences, Kumamoto University; the Department of Infectious Diseases and Immunology, Clinical Research Center, NHO Nagoya Medical Center; the Laboratory for Evolutionary Cell Biology of the Skin, School of Bioscience and Biotechnology, Tokyo University of Technology; and the Frontier Science Research Center, University of Miyazaki.
The author list includes Wright Andrews Ofotsu Amesimeku, Yoshihiro Nakata, Nami Monde, and 13 additional co-authors. The authors declare no conflicts of interest.
Lenacapavir is known to bind the mature capsid protein and block reverse transcription and nuclear import after a virus enters a cell. The new work demonstrates that the drug also binds the precursor Gag protein — the scaffold that builds new virions — even though precursor Gag and mature Gag have different structures and assembly states.
An important and unexpected finding of our study is that lenacapavir can bind to both precursor Gag and mature Gag, despite differences in their structures and assembly states.
Dr. Monde, Kumamoto University
Although p24 ELISA suggested that lenacapavir substantially inhibited HIV-1, both RT-dPCR and Vpr-HiBiT assays indicated that suppression of viral release required relatively high lenacapavir concentrations. The investigators attributed this discrepancy to a lenacapavir-induced reduction in p24 solubility, which led to an overestimation of the drug’s inhibitory effect on viral release.
The researchers also observed excessive intracellular Gag processing by the viral protease in the presence of lenacapavir, which contributed to impaired viral release. The drug also induced numerous abnormal, discrete clusters of Gag at the plasma membrane.

Using single-particle mass photometry and transmission electron microscopy, the team found that at 60 nanomolar lenacapavir, normal spherical virions of 100–130 nanometers largely disappeared. In their place appeared heterogeneous LEN-induced virus-like particles (LENiVLPs) exceeding 200 nanometers in diameter. These oversized particles still incorporate Gag and envelope glycoproteins and retain the ability to fuse with target cells, but structural defects prevent them from establishing a productive infection.
Kumamoto University, a national university on Kyushu, was established on May 31, 1949, by merging five predecessor institutions, including Kumamoto Medical College founded in 1896. The university operates the Center for AIDS Research on its Honjo-kuhonji campus, which hosts the Faculty of Life Sciences where Dr. Monde’s Department of Microbiology is based. It currently enrolls around 10,000 Japanese students and 500 international students across seven faculties and eight graduate schools.
The findings suggest lenacapavir disrupts late-stage assembly through dual mechanisms of capsid distortion and premature Gag cleavage.